Ivax paclitaxel
Executive Summary
Company expects to ship $30 mil. of the anticancer agent by the end of the year. Shipment of the generic version of Bristol's Taxol, which began Oct. 23, was delayed due to litigation by Bristol-Myers Squibb and American BioSciences (1"The Pink Sheet" Aug. 28, p. 8). Ivax' ANDA was approved Sept. 15